Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patent Exclusivity Reform Needed Due To Difficult Drug Environment – Hassan

Executive Summary

The fixed post-approval exclusivity period should be extended in light of the lengthening of the development process, Schering-Plough CEO Fred Hassan suggested during an interview with "The Pink Sheet"

You may also be interested in...



FDA Needs Communications Make-Over, Execs Say; Commish May Be First Step

FDA should expand and improve its external communications programs, panelists said during the FDA Alumni Association annual meeting in Washington, D.C. April 5

Drugs Should Get Longer Patents In Exchange For More Safety Data – Wood

Offering extended exclusivity, in advance, for drugs that address an unmet medical need could bring a necessary boost to research and development efforts, Vanderbilt University's Alastair Wood said

Schering Seeks Salvation In External Deals; Hassan Outlines Licensing Plan

The solution to the "innovation threat" facing big pharma lies in making deals outside the company, Schering-Plough CEO Fred Hassan said during an R&D update Nov. 1

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel